Comparison of the 5-fluorouracil-warfarin and capecitabine-warfarin drug interactions

Pharmacotherapy

Volumn 30, Issue 12, 2010, Pages 1259-1265

  Shah, Sachin R ^a,b   Martin, Randall ^a   Dowell, Jonathan E ^b,c   Ussery, Sarah M Gressett ^b  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

5 fluorouracil; 5 FU; Anticoagulation; Capecitabine; Drug interactions; Fluoropyrimidine; INR; International normalized ratio; Warfarin

Indexed keywords

CAPECITABINE; FLUOROURACIL; WARFARIN;

ADULT; ARTICLE; BLEEDING; CLINICAL ARTICLE; COMPARATIVE STUDY; DEEP VEIN THROMBOSIS; DRUG DOSE REDUCTION; FEMALE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY;

ANTICOAGULANTS; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; DRUG INTERACTIONS; FEMALE; FLUOROURACIL; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; WARFARIN;

EID: 78650210262     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.12.1259     Document Type: Article

References (23)

1. Shah HR, Ledbetter L, Diasio R, Saif MW. A retrospective study of coagulation abnormalities in patients receiving concomitant capecitabine and warfarin. Clin Colorectal Cancer 2006;5:354-8.
2. Davis DA, Fugate SE. Increasing warfarin dosage reductions associated with concurrent warfarin and repeated cycles of 5-fluorouracil therapy. Pharmacotherapy 2005;25:442-7.
3. Brown MC. An adverse interaction between warfarin and 5-fluorouracil. A case report and review of the literature. Chemotherapy 1999;45:392-5.
4. Brown MC. Multisite mucous membrane bleeding due to a possible interaction between warfarin and 5-fluorouracil. Pharmacotherapy 1997;17:631-3.
5. Carabino J, Wang F. International normalized ratio fluctuation with warfarin-fluorouracil therapy [letter]. Am J Health Syst Pharm 2002;59:875.
6. Kolesar JM, Johnson CL, Freeberg BL, Berlin JD, Schiller JH. Warfarin-5-FU interaction - a consecutive case series. Pharmacotherapy 1999;19:1445-9.
7. Yildirim Y, Ozyilkan O, Akcali Z, Basturk B. Drug interaction between capecitabine and warfarin: a case report and review of the literature. Int J Clin Pharmacol Ther 2006;44:80-2. (Pubitemid 43230590)
8. Isaacs K, Haim N. Adverse interaction between capecitabine and warfarin resulting in altered coagulation parameters and bleeding: case report and review of the literature. J Chemother 2005;17:339-42.
9. Janney LM, Waterbury NV. Capecitabine-warfarin interaction. Ann Pharmacother 2005;39:1546-51.
10. Copur MS, Ledakis P, Bolton M, et al. An adverse interaction between warfarin and capecitabine: a case report and review of the literature. Clin Colorectal Cancer 2001;1:182-4.
11. Buyck HC, Buckley N, Leslie MD, Plowman PN. Capecitabine-induced potentiation of warfarin [letter]. Clin Oncol (R Coll Radiol) 2003;15:297.
12. Yood MU, Quesenberry CP Jr, Alford SH, et al. An observational study examining the impact of capecitabine on warfarin antithrombotic activity and bleeding complications. Curr Med Res Opin 2006;22:307-14.
13. Blum JL. The role of capecitabine, an oral, enzymatically activated fluoropyrimidine, in the treatment of metastatic breast cancer. Oncologist 2001;6:56-64.
14. Rustum YM. Thymidylate synthase: a critical target in cancer therapy? Front Biosci 2004;9:2467-73.
15. U.S. Food and Drug Administration. Drugs@FDA: FDA approved drug products. Available from www.fda.gov/search/databases.html. Accessed September 12, 2009.
16. Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998;34:1274-81.
17. Giunta G. Warfarin-5-FU interactions [letter]. Ann Oncol 2006;17:176.
18. Camidge R, Reigner B, Cassidy J, et al. Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancer. J Clin Oncol 2005;23:4719-25.
19. Genentech. Xeloda (capecitabine) package insert. South San Francisco, CA; 2009.
20. APP Pharmaceuticals. Fluorouracil injection package insert. Schaumburg, IL; 2008.
21. Magagnoli M, Masci G, Castagna L, Morenghi E, Santoro A. High incidence of INR alteration in gastrointestinal cancer patients treated with mini-dose warfarin and 5-fluorouracil-based regimens. Ann Oncol 2006;17:174-6.
22. Magagnoli M, Masci G, Castagna L, et al. High incidence of haemostatic interference in cancer patients treated with FOLFOX regimen and concomitant minidose of warfarin. Br J Haematol 2005;129:709-10.
23. Magagnoli M, Castagna L, Masci G, Santoro A. Low-dose warfarin prophylaxis for catheter-associated thrombosis in cancer patients. Can it be safely associated with 5-fluorouracil-based chemotherapy? Oncologist 2004;9:594-5.